Related Experiment Video

Updated: Aug 27, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.3K

Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma

David J Benjamin1, Nataliya Mar2, Arash Rezazadeh Kalebasty2

  • 1Medical Oncology, Hoag Family Cancer Institute, Newport Beach, CA, USA.

Clinical Medicine Insights. Oncology
|October 3, 2022
PubMed

Insights

Immune checkpoint inhibitors (ICIs) revolutionized metastatic urothelial cancer (mUC) treatment. Combining erdafitinib with ICIs may improve outcomes for patients with FGFR+ mUC, addressing potential ICI resistance.

Area of Science:

  • Oncology
  • Genitourinary Cancer
  • Cancer Therapeutics

Background:

  • Metastatic urothelial cancer (mUC) treatment options were limited until immune checkpoint inhibitors (ICIs) emerged in 2016.
  • Molecular profiling identified subtypes of bladder cancer, including those with fibroblast growth factor receptor (FGFR) alterations.
  • Erdafitinib, a pan-FGFR inhibitor, gained approval in 2019 for advanced UC.

Purpose of the Study:

  • To investigate the potential for improved treatment outcomes in FGFR-altered metastatic urothelial cancer.
  • To explore the combination of erdafitinib and ICIs in mUC treatment.
  • To address the observed inferior response to ICIs in advanced FGFR+ UC.

Main Methods:

  • Review of current treatment paradigms for mUC.
  • Analysis of molecular subtypes, focusing on FGFR alterations.
  • Examination of ongoing clinical trials, including Phase IB/II studies combining erdafitinib with ICIs.

Main Results:

  • Evidence suggests potential for reduced efficacy of ICIs in FGFR-altered mUC.
  • The tumor microenvironment may play a role in ICI response in FGFR+ mUC.
  • Ongoing trials are evaluating combination therapies for enhanced efficacy.

Conclusions:

  • The combination of erdafitinib and ICIs shows promise for more robust and durable responses in FGFR+ mUC.
  • Targeting FGFR alterations alongside immune modulation represents a potential advancement in mUC therapy.
  • Further research and clinical trials are crucial to validate these findings.
Keywords:
FGFRUrothelial carcinomabladder cancercheckpoint inhibitorerdafitinibimmunotherapy

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.0K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

509

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
642
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K